In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Abbott, Karo Bio develop Type II diabetes drugs; ended

Executive Summary

Abbott Laboratories and Swedish pharmaceutical Karo Bio AB signed a three-year deal to develop Type II diabetes therapeutics. Abbott will use Karo Bio's nuclear receptor technology and potential drug candidates, and the partners will together handle research and preclinical development.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register